Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT03105882
Other study ID # InVivo-100-102
Secondary ID
Status Withdrawn
Phase N/A
First received March 29, 2017
Last updated March 15, 2018
Start date March 30, 2017
Est. completion date March 15, 2018

Study information

Verified date March 2018
Source InVivo Therapeutics
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Pilot Study of Clinical Safety and Feasibility of the Neuro-Spinal ScaffoldTM for the Treatment of Complete (AIS A) Traumatic Acute Spinal Cord Injury at the C5-T1 Neurological Levels The purpose of this study is to support an expansion to support marketing applications as well as future studies.


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date March 15, 2018
Est. primary completion date March 15, 2018
Accepts healthy volunteers No
Gender All
Age group 16 Years to 70 Years
Eligibility Inclusion Criteria:

- 16-70 years of age, inclusive

- AIS A classification of traumatic spinal cord injury with a neurological level within C5-T1 inclusive

- Recent injury

- Non-penetrating SCI

Exclusion Criteria:

- Terminally ill subjects not likely to be able to participate in follow-up

- Incomplete spinal cord injury (AIS B, C, D, and E injuries)

- No identifiable intra-spinal cavity following myelotomy/irrigation in the contused spinal cord in which a Scaffold can be placed

- Spinal cord injury associated with significant traumatic brain injury or coma that

- Radiographic or visual evidence of parenchymal dissociation or anatomic transection as determined by the Investigator where the contusion completely bridges a full cross-section of the spinal cord

- Subjects with spinal cord injuries directly due to gunshot, knife, or other penetrating wounds

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Neuro-Spinal Scaffold
Experimental: Neuro-Spinal Scaffold

Locations

Country Name City State
Canada Toronto Western Hospital Toronto Ontario

Sponsors (1)

Lead Sponsor Collaborator
InVivo Therapeutics

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Other American Spinal Injury Association Impairment Scale (AIS) improvement of one or more grade International Standards for Neurological Classification of Spinal Cord Injury (ISNCSCI) Exams 6 months
Other Improvements in motor and sensory scores ISNCSCI exams 6 months
Other Improvements in Graded Redefined Assessment of Strength, Sensibility and Prehension (GRASSP) GRASSP Assessment 6 months
Primary Incidence of all Adverse Device Effects of any kind/seriousness. 6 Months